IRIS UniCatt

Giampietro, Antonella
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 4.819
AS - Asia 3.549
EU - Europa 3.340
SA - Sud America 838
AF - Africa 104
OC - Oceania 8
Continente sconosciuto - Info sul continente non disponibili 5
AN - Antartide 1
Totale 12.664
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 4.651
SG - Singapore 1.538
DE - Germania 1.139
CN - Cina 781
BR - Brasile 680
IT - Italia 514
VN - Vietnam 460
SE - Svezia 424
FR - Francia 274
UA - Ucraina 185
GB - Regno Unito 166
BD - Bangladesh 126
IE - Irlanda 123
IN - India 115
RU - Federazione Russa 115
FI - Finlandia 111
ID - Indonesia 108
JP - Giappone 100
PL - Polonia 87
CA - Canada 85
HK - Hong Kong 75
AR - Argentina 63
NL - Olanda 52
MX - Messico 47
IQ - Iraq 39
TR - Turchia 32
ES - Italia 30
ZA - Sudafrica 28
AT - Austria 27
BE - Belgio 25
EC - Ecuador 25
KR - Corea 20
CO - Colombia 18
PK - Pakistan 18
VE - Venezuela 18
EG - Egitto 17
SA - Arabia Saudita 17
IR - Iran 15
AE - Emirati Arabi Uniti 13
MA - Marocco 13
UZ - Uzbekistan 13
CL - Cile 12
PE - Perù 10
AZ - Azerbaigian 9
CI - Costa d'Avorio 9
KE - Kenya 9
MY - Malesia 9
AL - Albania 8
CZ - Repubblica Ceca 8
JM - Giamaica 8
KZ - Kazakistan 8
PH - Filippine 8
PY - Paraguay 8
MD - Moldavia 7
PT - Portogallo 7
RO - Romania 7
TN - Tunisia 7
JO - Giordania 6
LK - Sri Lanka 6
BG - Bulgaria 5
CR - Costa Rica 5
DO - Repubblica Dominicana 5
NP - Nepal 5
AU - Australia 4
CH - Svizzera 4
HN - Honduras 4
LB - Libano 4
OM - Oman 4
RS - Serbia 4
SN - Senegal 4
AM - Armenia 3
BH - Bahrain 3
ET - Etiopia 3
EU - Europa 3
GE - Georgia 3
GR - Grecia 3
GT - Guatemala 3
HU - Ungheria 3
TT - Trinidad e Tobago 3
A2 - ???statistics.table.value.countryCode.A2??? 2
BB - Barbados 2
BO - Bolivia 2
BS - Bahamas 2
BY - Bielorussia 2
DK - Danimarca 2
GA - Gabon 2
GH - Ghana 2
IL - Israele 2
KG - Kirghizistan 2
NG - Nigeria 2
NO - Norvegia 2
NZ - Nuova Zelanda 2
QA - Qatar 2
UY - Uruguay 2
AO - Angola 1
AQ - Antartide 1
BA - Bosnia-Erzegovina 1
BW - Botswana 1
CG - Congo 1
CY - Cipro 1
Totale 12.644
Salva come PNG Salva come JPEG
Città #
Singapore 847
Chandler 582
San Jose 471
Ashburn 457
New York 198
Ho Chi Minh City 167
Beijing 158
Los Angeles 137
Rome 119
Dublin 115
San Mateo 108
Hanoi 100
Lauterbourg 92
Jakarta 87
The Dalles 86
Ann Arbor 82
Tokyo 82
Hefei 80
Moscow 76
Warsaw 76
Jacksonville 73
Munich 73
São Paulo 73
Milan 72
Dallas 71
Fairfield 68
Wilmington 68
Hong Kong 67
Frankfurt am Main 65
Marseille 62
Boston 61
Tukwila 58
Nürnberg 55
St Louis 52
Houston 48
Nanjing 48
Chicago 45
Helsinki 45
Bremen 44
Seattle 44
Princeton 41
Cattolica 40
Montreal 35
Santa Clara 35
Dearborn 34
Redwood City 31
Kent 30
Shanghai 30
Boardman 29
Denver 29
London 29
Orem 29
Woodbridge 29
Turku 26
Buffalo 25
Brooklyn 24
Brussels 24
Cambridge 24
Da Nang 24
Nanchang 24
Nuremberg 23
Hangzhou 22
Rio de Janeiro 22
Lawrence 21
Mountain View 20
Zhengzhou 19
Atlanta 17
Hyderabad 17
North Bergen 17
University Park 17
Amsterdam 16
Belo Horizonte 16
Guangzhou 16
Phoenix 16
Mumbai 15
Seoul 15
Shenyang 15
Augusta 14
Council Bluffs 14
Fremont 14
Haiphong 14
Johannesburg 14
Toronto 14
Mexico City 13
Paris 13
Vienna 13
Baghdad 12
Düsseldorf 12
Norwalk 12
Poplar 12
Stockholm 12
Tashkent 12
Bexley 11
Dhaka 11
Kunming 11
Lappeenranta 11
Leawood 11
Porto Alegre 11
Santo André 11
Thái Nguyên 11
Totale 6.491
Salva come PNG Salva come JPEG
Nome #
Hypophysitis Outcome and Factors Predicting Responsiveness to Glucocorticoid Therapy: A Prospective and Double-Arm Study. 333
Cancer screening in patients with acromegaly: a plea for a personalized approach and international registries 318
Radically resected pituitary adenomas: prognostic role of Ki 67 labeling index in a monocentric retrospective series and literature review 307
Double pituitary adenomas 238
Role of a mini-invasive approach in the diagnosis and treatment of tubo-peritoneal infertility as an altenative to IVF [Il ruolo di un approccio chirurgico mini-invasivo nella diagnosi e trattamento della sterilità tubo-peritoneale in alternativa alla FIVET] 227
Coenzyme Q10 evaluation in pituitary-adrenal axis disease: preliminary data. 216
Typical and Atypical Pituitary Adenomas: A Single-Center Analysis of Outcome and Prognosis 212
An Overview of Diagnosis of Primary Autoimmune Hypophysitis in a Single Prospective Monocentric Experience 202
Effects of gherlin administration on endocrine and metabolic parameters in obese women with polycystic ovary syndrome 200
Non Alcoholic Fatty Liver Disease is Associated with Increased GHBP and Reduced GH/IGF-I Levels 199
Treatment with octreotide LAR in clinically non-functioning pituitary adenoma: results from a case-control study 197
Nonalcoholic fatty liver disease is associated with increased GHBP and reduced GH/IGF-I levels 190
Male fertility and reduction in semen parameters: A single tertiary-care center experience 190
Circulating endothelial cells as marker of endothelial damage in male hypogonadism 189
NOVEL BIOMARKERS OF ANDROGEN DEFICIENCY FROM SEMINAL PLASMA PROFILING USING HIGH-RESOLUTION MASS SPECTROMETRY. 178
Factors predicting pasireotide responsiveness in somatotroph pituitary adenomas resistant to first-generation somatostatin analogues: An immunohistochemical study 174
Isolated growth hormone deficiency: clinical entity? 167
Effects of ghrelin administration on endocrine and metabolic parameters in obese women with polycystic ovary syndrome 161
Circulating endothelial cells as marker of endothelial damage in male hypogonadism 159
Pancreatic neuroendocrine tumors in MEN1 disease: a mono-centric longitudinal and prognostic study 158
Influence of diabetes mellitus on vertebral fractures in men with acromegaly 153
Radically resected pituitary adenomas: prognostic role of Ki67 labeling index in monocentric retrospective series and literature review 151
The effect of treatment with growth hormone on fertility outcome in eugonadal women with growth hormone deficiency: report of four cases and review of the literature 149
Significant GH-deficiency after long-term cure by surgery in adult patients with Cushing s disease 149
The Changing Clinical Spectrum of Hypophysitis 148
Glucocorticoid replacement therapy and vertebral fractures in hypopituitary adult males with GH deficiency 147
Galectin-3 and Estrogen Receptor Alpha as Prognostic Markers in Prolactinoma: Preliminary Results From a Pilot Study 145
Pegvisomant and Pasireotide LAR as second line therapy in acromegaly: clinical effectiveness and predictors of response 145
DIAGNOSIS OF ENDOCRINE DISEASE: Primary Empty Sella: a comprehensive review 144
GH receptor isoforms and skeletal fragility in acromegaly 140
Fertility and hypopituitarism 139
Factors predicting pasireotide responsiveness in somatotroph pituitary adenomas resistant to first-generation somatostatin analogues: an immunohistochemical study. 137
Pasireotide and Pegvisomant Combination Treatment in Acromegaly Resistant to Second Line Therapies: A Longitudinal Study 133
Aggressive PitNETs and Potential Target Therapies: A Systematic Review of Molecular and Genetic Pathways 131
Long-term treatment of somatostatin analog-refractory growth hormone-secreting pituitary tumors with pegvisomant alone or combined with long-acting somatostatin analogs: a retrospective analysis of clinical practice and outcomes 128
The changing clinical spectrum of endocrine adverse events in cancer immunotherapy 127
Pancreas as an Unusual Metastatic Site of Medullary Thyroid Carcinoma: A Case of Very Long-term Follow-up Under Prolonged Treatment with Somatostatin Analogues 126
Quantitative Analysis of the Seminal Plasma Proteome in Secondary Hypogonadism 126
Reappraising the Role of Trans-Sphenoidal Surgery in Prolactin-Secreting Pituitary Tumors. 126
First Case of Mature Teratoma and Yolk Sac Testis Tumor Associated to Inherited MEN-1 Syndrome. 123
Empty sella syndrome: Multiple endocrine disorders. 120
Autoantibody reactivity profile of primary autoimmune hypophysitis patients: preliminary results 120
Genes of the “regulation of lymphocyte activation” pathway may influence immune cells infiltration in growth hormone secreting pituitary tumors 119
The Pathogenic RET Val804Met Variant in Acromegaly: A New Clinical Phenotype? 119
Effects of glucocorticoid replacement therapy in patients with pituitary disease: A new perspective for personalized replacement therapy 118
Synchronous Bilateral Adrenalectomy in ACTH-dependent Hypercortisolism: Predictors, Biomarkers and Outcomes 116
CD68+ and CD8+ immune cells are associated with the growth pattern of somatotroph tumors and response to first generation somatostatin analogs 115
Hypothalamitis and pituitary atrophy 115
Neuro-radiological features can predict hypopituitarism in primary autoimmune hypophysitis 114
Human leucocyte antigens coeliac haplotypes and primary autoimmune hypophysitis in caucasian patients 113
Multidisciplinary management of difficult/aggressive growth-hormone pituitary neuro-endocrine tumors 111
Characteristics and outcomes of Italian patients from the observational, multicentre, hypopituitary control and complications study (HypoCCS) according to tertiles of growth hormone peak concentration following stimulation testing at study entry 110
The Role of Growth Hormone Receptor Isoforms and Their Effects in Bone Metabolism and Skeletal Fragility 110
Growth hormone receptor isoforms and fracture risk in adult-onset growth hormone-deficient patients. 109
Pituitary Enlargement and Hypopituitarism in Patients Treated with Immune Checkpoint Inhibitors: Two Sides of the Same Coin? 108
Pregnancy in Autoimmune Hypophysitis: Management of a Rare Condition 108
Glucose metabolism outcomes in acromegaly patients on treatment with pasireotide-LAR or pasireotide-LAR plus Pegvisomant 108
Unveiling the Etiopathogenic Spectrum of Hypophysitis: A Narrative Review 106
Understanding the effect of acromegaly on the human skeleton. 106
Vertebral fractures in patients with acromegaly: a 3-year prospective study 105
Effects of Pegvisomant and Pasireotide LAR on Vertebral Fractures in Acromegaly Resistant to First-generation SRLs. 105
Tumour-infiltrating cytotoxic T lymphocytes in somatotroph pituitary neuroendocrine tumours 105
Tumor features in adult papillary and adamantinomatous craniopharyngioma: neuroradiological evaluation of pituitary-hypothalamic-axis dysfunction and outcome prediction 104
The Differential Diagnosis between Pseudo Cushing's Syndrome and True Cushing's Syndrome in a Septic Patient in the Pre-Agonal Phase: A Case Report 104
IGF-I levels during standard Lanreotide dose predicts biochemical outcome of high-frequency regimen in acromegaly 100
Effects of pegvisomant and somatostatin receptor ligands on incidence of vertebral fractures in patients with acromegaly. 100
Multidimensional geriatric evaluation in acromegaly: a comparative cross-sectional study 99
Short- and long-term responsiveness to low dose growth hormone (GH) in adult GH deficiency: Role of GH receptor polymorphism. 98
Trouillas's Grading and Post-Surgical Tumor Residue Assessment in Pituitary Adenomas: The Importance of the Multidisciplinary Approach 97
The multi-biomarker acro-TIME score predicts fg-SRLs response: preliminary results of a retrospective acromegaly cohort 95
Clinical management of teratoma, a rare hypothalamic-pituitary neoplasia 95
Cytokines and chemokines modulate the growth of pituitary adenoma/neuroendocrine tumors: preliminary results of a monocenter prospective pilot study 94
Empty sella syndrome: an update 92
Acromegaly can be cured by first-line pasireotide treatment? 91
Acromegaly in the elderly patients 91
Trouillas’s Grading and Post-Surgical Tumor Residue Assessment in Pituitary Adenomas: The Importance of the Multidisciplinary Approach 90
Prevalence of morphometric vertebral fractures in "difficult" patients with acromegaly with different biochemical outcomes after multimodal treatment. 90
Second line treatment of acromegaly: Pasireotide or Pegvisomant? 85
Tumor features in adult papillary and adamantinomatous craniopharyngioma: neuroradiological evaluation of pituitary-hypothalamic-axis dysfunction and outcome prediction 85
De-escalation treatment with pasireotide for acromegaly: a long-term experience 84
GH receptor polymorphisms guide second-line therapies to prevent acromegaly skeletal fragility: preliminary results of a pilot study 82
Systemic comorbidities of acromegaly in real-life experience: which difference among young and elderly patients? 81
Pegvisomant and Pasireotide LAR as second line therapy in acromegaly: clinical effectiveness and predictors of response 81
Psychological complications in patients with acromegaly: relationships with sex, arthropathy, and quality of life 80
Solitary Metastatic Melanoma of the Pituitary Gland: Report of Two Cases and Literature Review 80
Clinical implications of the 2022 WHO classification on the multidisciplinary management of PitNETS patients 79
Bone health and skeletal fragility in second- and third-line medical therapies for acromegaly: preliminary results from a pilot single center experience 79
A Toluene-induced Infundibulo-neuro-hypophysitis: Presentation of a New Cause of Hypophysitis Secondary to Toxic Exposure and Review on Toluene Inhalation Endocrine Effects 77
Colon Cancer Presenting as Pituitary Mass and Hypopituitarism: Recognition and Multidisciplinary Approach of a Rare Case 76
Treatment of Acromegalic Osteopathy in Real-life Clinical Practice: The BAAC (Bone Active Drugs in Acromegaly) Study 75
Factors associated with disease control failure in acromegaly patients treated with pegvisomant: an ACROSTUDY analysis 74
Long-term pasireotide-LAR treatment in the personalized therapy of patients with complex acromegaly: a collection of clinical experiences 72
The clinicopathological PANOMEN-3 classification predicts pituitary adenoma prognosis: a real-world retrospective single center study of a surgically treated cohort 69
Cholecalciferol Use Is Associated With a Decreased Risk of Incident Morphometric Vertebral Fractures in Acromegaly 66
Bone safety of dual-release hydrocortisone in patients with hypopituitarism. 65
Partial response to first generation SSA guides the choice and predict the outcome of second line therapy in acromegaly 63
Markers of humoral and cell-mediated immune response in primary autoimmune hypophysitis: a pilot study 62
Lights or shadows, a promising future for positron emission tomography in pituitary tumors: a systematic review 61
Tumour-infiltrating cytotoxic T lymphocytes in somatotroph pituitary neuroendocrine tumours 60
Vitamin D in pituitary driven osteopathies 58
Totale 12.576
Salva come PNG Salva come JPEG
Categoria #
all - tutte 48.409
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 48.409
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20215 0 0 0 0 0 0 0 0 0 0 0 5
2021/2022617 30 33 7 47 74 27 10 112 28 26 85 138
2022/20231.516 173 207 123 252 80 211 89 127 157 13 53 31
2023/2024717 32 160 17 32 31 142 35 8 28 34 93 105
2024/20251.843 30 40 124 75 101 74 37 67 273 188 395 439
2025/20265.901 736 221 421 769 846 287 884 313 297 432 590 105
Totale 12.837